Immix Biopharma, Inc. (IMMX)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$79.3M
Cash & Equivalents
$9.8M
Quarterly Burn Rate
24 mo
Est. Cash Runway
$791M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2026-12-01 Phase2 Readout —

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT06097832 Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis PHASE2 Recruiting 40

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for IMMX.

SEC EDGAR Filings

All SEC filings for Immix Biopharma, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.